IR Overview

Cyclo Therapeutics, Inc. (Nasdaq: CYTH)

Cyclo Therapeutics, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (Clinical NCT02939547, NCT02912793 and NCT03893071) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website:

The CTD division provides the world’s widest range of cyclodextrin-based fine chemicals available from a single source in both research and commercial quantities to life science laboratories and commercial manufacturers world-wide. For additional information, visit the division’s website:

Recent News

Company Information

Cyclo Therapeutics, Inc.
P.O. Box 1180
Alachua, FL 32616-1180

Issue Type: Common Stock
Sector: Healthcare
Industry: Drugs

Management Team

N. Scott Fine
Chairman & CEO

Jeffrey L. Tate, Ph.D.
Director, COO & CQO

Sharon H. Hrynkow, Ph.D.
CSO & SVP of Medical Affairs

Joshua Fine

Michael Lisjak
Global Head of Regulatory Affairs & SVP Business Development

Investor Relations

Sitrick and Company
Mark Veverka
90 New Montgomery Suite 1301
San Francisco, CA 94105

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598


WithumSmith+Brown, PC
200 S. Orange Ave, Suite 1200
Orlando, FL 32801